Regarding the most commonly mutated pathway in NPC, a single drug or a combination of drugs targeting the PI3K/Akt/mTOR signaling pathway has been clinically used or studied in preclinical trials. The gene discussed is PIK3CA; the disease is nasopharyngeal carcinoma.